Banner - NPPA Connect
NP/PA Connect
News
Media
Around the PracticeBetween The LinesCase-Based Peer PerspectiveClinical Case CollectiveDermViewExpert PerspectivesFellows Face OffFrontline ForumMedical World NewsPatient PerspectivesPodcastsReadout360Recognize and Refer
Conferences
Conference CoverageConference Listing
Events
Case-Based Roundtable
More
Publication
Dermatology Times
CME/CE
Resources
DermIQInteractive ToolsJob BoardPartner PerspectivesPerspectives in DermatologyPollsSponsored ContentSponsored ResourcesSpot Test
Editorial Advisory Board
Partners

Subscribe

  • NP/PA Connect
  • News
  • Media
  • Conferences
  • Events
  • Publication
  • CME/CE
  • Resources
  • Editorial Advisory Board
  • Partners
  • Subscribe
  • Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
    • Non-Melanoma Skin Cancers
  • Vitiligo
  • Wound Care
Advertisement

Jerry Brewer, MD, MS, FACMS

Advertisement

Articles by Jerry Brewer, MD, MS, FACMS

Jerry Brewer, MD, MS

When to Call a Time Out on Mohs Surgery

ByLauren Buchanan, MA, Managing Editor,Jerry Brewer, MD, MS, FACMS
May 7th 2023

Jerry Brewer, MD, MS, shared pearls on reasons to avoid or discontinue Mohs surgery and keeping calm with stressed, vulnerable patients.

Advertisement

Latest Updated Articles

  • Jerry Brewer, MD, MS
    When to Call a Time Out on Mohs Surgery

    Published: May 7th 2023 | Updated:



Advertisement
Advertisement

Trending on Dermatology Times

1

AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review

2

Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis

3

FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA

4

Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older

5

Introducing Dermatology Times NP/PA Connect

  • About
  • Advertise
  • Contact Us
  • Job Board
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy Policy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us